Flagship Biosciences Customizes Assay Development and Tissue Image Analysis
News Apr 21, 2015
Flagship Biosciences has announced the utilization of its wet assay development and image analysis quantification capabilities for RNAscope® RNA in situ hybridization (ISH) from Advanced Cell Diagnostics, Inc. (ACD). The two companies will work to optimize quantitative image analysis of in situ hybridization in tissue samples in Flagship’s CLIA laboratory.
The increasing use of RNA ISH in companion diagnostics for drug development and CDx strategies require multidisciplinary expertise in pathology, assay development and image analysis in a CLIA laboratory environment.
Flagship has leveraged ACD’s industry-leading in situ hybridization assay platform to support its clients ongoing CLIA based clinical trials to enable the utilization of RNAscope technology in CDx trials.
“Flagship focusses on delivering unique fit-for-purpose quantitative pathology results, with advanced experience in both IHC and ISH assay development and custom image analysis. Over the last five years, our customers have benefited from our ability to focus our resources on unique scientific measurements using image analysis tools, which are able to overcome the obstacles barring clinical utility. By partnering with ACD, we are able to provide the state-of-the art in situ hybridization approaches, with quantitative endpoints suitable for a companion diagnostic strategy.” said Dr. Joseph Krueger, Chief Science Officer for Flagship Biosciences.
“One critical feature of the RNAscope assay is its ability to detect individual RNA molecules within the context of tissue morphology. This enables a quantitative expression readout at individual cell level, which opens the door to a higher level of precision biomarker analysis,” said Dr. Xiao-Jun Ma, Chief Scientific Officer of ACD. “We are very pleased to work with Flagship to fully leverage this advantage, which is particularly important for the development of companion diagnostics.”
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE